LCM
IOVA icon

Laurion Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Laurion Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-637,742
Closed -$5.18M – 568
2023
Q4 		$5.18M Buy
+637,742
New +$3.34M 0.04% 243
2022
Q2 		– Sell
-22,558
Closed -$376K – 589
2022
Q1 		$376K Buy
+22,558
New +$349K ﹤0.01% 408
2020
Q3 		– Sell
-49,495
Closed -$1.36M – 982
2020
Q2 		$1.36M Buy
49,495
+35,895
+264% +$1.18M 0.02% 363
2020
Q1 		$407K Buy
+13,600
New +$360K ﹤0.01% 607

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Laurion Capital Management's IOVA Position: Q1 2024 in Review

Laurion Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 637,742 shares — an estimated $5.18M sold.

Laurion Capital Management first reported a position in IOVA in Q1 2020 and held it in 4 quarters. The position peaked at $5.18M in Q4 2023. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Laurion Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Laurion Capital Management sold 637,742 Iovance Biotherapeutics shares in Q1 2024, an estimated $5.18M.
  • Laurion Capital Management first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 4 quarters.
  • Laurion Capital Management's Iovance Biotherapeutics position peaked at $5.18M in Q4 2023.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.